At a Glance

Lombard Medical Technologies (LMT) is the holding company of a medical devices group that aims to become a leading developer of innovative solutions for the treatment of vascular and other diseases.


 In particular LMT is:

producing the next generation of vascular devices addressing the unmet needs of the aortic aneurysm market; and

targeting potential market opportunities valued at over $1 billion.

 

The Group has two main divisions:

the Cardiovascular Devices Division developing and commercialising innovative devices to treat vascular conditions such as Abdominal Aortic Aneurysms (AAA); and

the Polymer Coatings Division which develops programmable, multi-drug delivery coatings for coronary stents as well as coatings for other medical devices such as catheters.

 

Marketed Products

Aorfix™ A second-generation bifurcated stent graft, CE Mark approved in the EU for the treatment of Abdominal Aortic Aneurysms (AAA). 
EndoRefix™ A patented endovascular stapling device that has CE Mark approval for the fixation of endovascular stent grafts.  FDA approval for this indication  is expected later this [2008] year following the completion of a small clinical trial.

Lead Development Products

Aorfix™ (US)IDE approval has been received from the FDA and pivotal trials of the AAA began 2006, PMA filing with the FDA is expected in 2009.
Thoracic stent graftA stent graft for the treatment of Thoracic Aortic Aneurysms (TAA).

Distributors

Distributors Aorfix™ is currently marketed by distributors in 16 countries. (Click on distributors for a full list and contact details)

Technologies

PEP™This programmable drug elution profile (PEP™) coating can adjust the timing and amount of one or two drugs released by a drug eluting stent over one month or more.

 

Updated March 2008

 


 




Related Links

Overview

Strategy